Send to

Choose Destination
Transpl Int. 2015 Jul;28(7):820-7. doi: 10.1111/tri.12544. Epub 2015 Mar 6.

Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis.

Author information

Division of Transplantation/Department of Surgery, Medical University of Vienna, Vienna, Austria.
Division of Nephrology and Dialysis/Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
Section for Medical Statistics, Medical University of Vienna, Vienna, Austria.


While belatacept has shown favorable short- and midterm results in kidney transplant recipients, only projections exist regarding its potential impact on long-term outcome. Therefore, we performed a retrospective case-match analysis of the 14 belatacept patients originally enrolled in the phase II multicenter trial at our center. Fifty six cyclosporine (CyA)-treated patients were matched according to age at transplantation, first/retransplant, and donor type. Ten years after kidney transplantation, kidney function remained superior in belatacept-treated patients compared with the CyA control group. Moreover, none of the belatacept-treated patients had donor-specific antibodies ≥10 years post-transplantation compared with 38.5% of tested CyA-treated subject (0/10 vs. 5/13; P = 0.045). Notably, however, patient and graft survival was virtually identical in both groups (71.4% vs. 71.3%; P = 0.976). In the present single-center study population, patients treated with belatacept demonstrated a patient and graft survival at 10 years post-transplant which was comparable to that of similarly selected CNI-treated patients. Larger studies with sufficient statistical power are necessary to definitively determine long-term graft survival with belatacept.


belatacept; immunosuppression; kidney transplantation; long-term outcome

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center